AskBio to collaborat
AskBio to collaborate with Belief BioMed to explore the potential of new gene therapies
25 sept. 2024 08h00 HE | Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, N.C., USA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media  AskBio and Belief BioMed will work together to advance potential gene...
AskBio receives FDA
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson’s disease
11 juil. 2024 08h00 HE | Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, N.C., USA, July 11, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media  AB-1005 (formerly known as AAV2-GDNF) is being studied for the treatment of...
AskBio Initiates Rec
AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial
25 juin 2024 08h00 HE | Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- REGENERATE-PD, which is now enrolling, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell line-derived neurotrophic...
AskBio Announces Nin
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting 2024
02 mai 2024 08h00 HE | Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG,...
AskBio receives FDA
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
18 avr. 2024 08h00 HE | Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, NC, USA, April 18, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1002 is being studied for the treatment of adults with non-ischemic...
AskBio presents 18-m
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’s disease
16 avr. 2024 08h03 HE | Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany, and Research Triangle Park, NC, USA, April 16, 2024 (GLOBE NEWSWIRE) --   Not intended for UK Media AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the...
Mansuo Shannon, PhD
AskBio Names Mansuo Shannon Chief Scientific Officer
09 avr. 2024 08h00 HE | Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., April 09, 2024 (GLOBE NEWSWIRE) -- Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and CompanyCo-Founder and former Chief...
First patient random
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
13 févr. 2024 08h10 HE | Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany and Research Triangle Park, NC, USA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1002 is an investigational gene therapy for the treatment of adults with...
R. Jude Samulski, PhD
AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)
05 janv. 2024 08h11 HE | Asklepios BioPharmaceutical, Inc. (AskBio)
Research Triangle Park, N.C., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer...
AskBio Phase Ib tria
AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary endpoint
04 janv. 2024 02h30 HE | Asklepios BioPharmaceutical, Inc. (AskBio)
Berlin, Germany/Research Triangle Park, North Carolina, USA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Not intended for UK Media AB-1005 (AAV2-GDNF), an investigational gene therapy for the...